Q3 Earnings Estimate for Novavax Issued By Zacks Research

Novavax, Inc. (NASDAQ:NVAX) – Analysts at Zacks Research issued their Q3 2027 earnings per share estimates for shares of Novavax in a research report issued on Thursday, March 19th. Zacks Research analyst Team expects that the biopharmaceutical company will earn ($0.01) per share for the quarter. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax’s Q4 2027 earnings at $0.08 EPS.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.77. Novavax had a negative return on equity of 673.17% and a net margin of 39.19%.The business had revenue of $136.40 million during the quarter, compared to analysts’ expectations of $90.26 million. During the same quarter last year, the business posted ($0.51) EPS. The business’s quarterly revenue was up 66.6% compared to the same quarter last year.

NVAX has been the subject of several other research reports. Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright lifted their price objective on shares of Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings upgraded shares of Novavax from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. Jefferies Financial Group reissued a “buy” rating on shares of Novavax in a report on Thursday, March 12th. Finally, BTIG Research restated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $11.88.

Novavax Stock Down 1.2%

Shares of NASDAQ:NVAX opened at $9.62 on Monday. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $11.97. The firm’s 50 day moving average price is $9.27 and its 200 day moving average price is $8.23. The company has a quick ratio of 2.10, a current ratio of 2.13 and a debt-to-equity ratio of 5.93. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of 3.99 and a beta of 2.54.

Institutional Trading of Novavax

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVAX. Hsbc Holdings PLC purchased a new stake in shares of Novavax during the 4th quarter worth approximately $394,000. Invesco Ltd. grew its position in shares of Novavax by 12.9% in the 4th quarter. Invesco Ltd. now owns 259,380 shares of the biopharmaceutical company’s stock valued at $1,743,000 after buying an additional 29,704 shares during the last quarter. VARCOV Co. acquired a new stake in Novavax during the 4th quarter worth $263,000. Virtus Investment Advisers LLC raised its stake in Novavax by 67.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 104,019 shares of the biopharmaceutical company’s stock worth $699,000 after acquiring an additional 41,866 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Novavax in the fourth quarter valued at $145,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.